Bioprocessing Companies Push Limits of Upstream Technologies
Goal Is to Maximize Efficiency in Bioprocess Operations
Vertex’s David Altshuler Humanizes Drug Discovery
Lessons from Vertex’s Small Molecule Drug Development Program for Cystic Fibrosis
Brexit’s Effect on U.K. Life Sciences
Making the Nation a One-Stop Regulatory Engine for Innovation
10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
Audrey Chang Ph.D.
Audrey Chang, Ph.D., serves as head of development services, at the BioReliance® portfolio of MilliporeSigma.